Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial

Abstract

Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown unprecedented efficacy in weight loss and improving metabolic parameters in clinical trials. However, the durability of these benefits after treatment cessation remains poorly understood. This study aimed to investigate the effect of tirzepatide cessation on body weight change in people with obesity or overweight. This real-world, observational 26-week follow-up study included participants who completed 52 weeks' study treatment during SURMOUNT-CN (NCT05024032). The analysis excluded participants who received anti-obesity medications or bariatric procedures during the 26-week follow-up. Key outcomes were the changes in body weight and waist circumference after 26 weeks, from treatment cessation (Week 52) and trial baseline (Week 0), by the SURMOUNT-CN treatment groups (tirzepatide 10 or 15 mg, or placebo). Overall, 152 participants were included (tirzepatide 10 mg: n = 57; tirzepatide 15 mg: n = 51; placebo: n = 44). Following treatment cessation (Week 52), the mean (SD) percentage changes in body weight at Week 78 were 9.1% (7.4), 12.3% (9.9), and 1.8% (5.2), and the absolute changes in waist circumference were 2.9 cm (7.5), 5.5 cm (6.5) and -0.5 cm (5.6), in tirzepatide 10 and 15 mg, and placebo groups, respectively. From trial baseline to Week 78, the mean (SD) net percentage weight changes were -8.7% (6.9), -10.6% (10.2), and -2.5% (7.0), and the changes in waist circumference were -10.5 cm (8.1), -10.6 cm (9.3) and -4.0 cm (7.2), in the tirzepatide 10 and 15 mg, and placebo groups, respectively. At Week 78, residual improvements in multiple cardiometabolic indicators were evident in the tirzepatide groups. Despite weight gain following tirzepatide cessation, participants achieved a large net weight loss and reduction in waist circumference from trial baseline to Week 78, with residual improvements in several cardiometabolic indicators.

Keywords

obesity / overweight / tirzepatide / GLP-1 / GIP / body weight

References

[1] Kessler C . Pathophysiology of obesity. Nurs Clin North Am 2021; 56: 465- 78.

[2] Pan XF , Wang L , Pan A . Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol 2021; 9: 373- 92.

[3] Heymsfield SB , Wadden TA . Mechanisms, pathophysiology, and management of obesity. N Engl J Med 2017; 376: 254- 66.

[4] Evert AB , Franz MJ . Why weight loss maintenance is difficult. Diabetes Spectr 2017; 30: 153- 6.

[5] Zeng Q , Li N , Pan XF et al. Clinical management and treatment of obesity in China. Lancet Diabetes Endocrinol 2021; 9: 393- 405.

[6] Nutrition and Metabolic Management Branch of China International Exchange and Promotive Association for Medical and Health Care, Clinical Nutrition Branch of Chinese Nutrition Society, Chinese Diabetes Society, Chinese Society for Parenteral and Enteral Nutrition, Chinese Clinical Nutritionist Center of Chinese Medical Doctor Association. Guidelines for medical nutrition treatment of overweight/obesity in China (2021). Asia Pac J Clin Nutr 2022; 31: 450- 82.

[7] Hall KD , Kahan S . Maintenance of lost weight and long-term management of obesity. Med Clin North Am 2018; 102: 183- 97.

[8] Bray GA , Kim KK , Wilding JPH . Obesity:a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev 2017; 18: 715- 23.

[9] Apovian CM , Aronne LJ , Bessesen DH et al. Pharmacological management of obesity:an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 342- 62.

[10] Garvey WT , Mechanick JI , Brett EM et al. American Association Of Clinical Endocrinologists and American College Of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 2016; 22: 1- 203.

[11] Grunvald E , Shah R , Hernaez R et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology 2022; 163: 1198- 225.

[12] Wharton S , Lau DCW , Vallis M et al. Obesity in adults:a clinical practice guideline. CMAJ 2020; 192: E875- 91.

[13] Noria SF , Shelby RD , Atkins KD et al. Weight regain after bariatric surgery:scope of the problem, causes, prevention, and treatment. Curr Diab Rep 2023; 23: 31- 42.

[14] Sjöström L , Rissanen A , Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167- 72.

[15] Smith SR , Weissman NJ , Anderson CM et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245- 56.

[16] Wilding JPH , Batterham RL , Davies M et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide:the STEP 1 trial extension. Diabetes Obes Metab 2022; 24: 1553- 64.

[17] Rubino D , Abrahamsson N , Davies M et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity:the STEP 4 Randomized Clinical Trial. JAMA 2021; 325: 1414- 25.

[18] Aronne LJ , Sattar N , Horn DB et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity:the SURMOUNT-4 Randomized Clinical Trial. JAMA 2024; 331: 38- 48.

[19] James WP , Astrup A , Finer N et al. Effect of sibutramine on weight maintenance after weight loss:a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119- 25.

[20] Flore G , Preti A , Carta MG et al. Weight maintenance after dietary weight loss:systematic review and meta-analysis on the effectiveness of behavioural intensive intervention. Nutrients 2022; 14: 1259.

[21] Chen K , Chen L , Shan Z et al. Beinaglutide for weight management in Chinese individuals with overweight or obesity:a phase 3 randomized controlled clinical study. Diabetes Obes Metab 2024; 26: 690- 8.

[22] Pi-Sunyer X , Astrup A , Fujioka K et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11- 22.

[23] Zhu HJ , Pan H , Gong FY et al. [A comparison of the efficacy and safety of domestic orlistat and imported orlistat in Chinese overweight and obese patients]. Zhonghua Nei Ke Za Zhi 2009; 48: 825- 9.

[24] Ryan DH , Yockey SR . Weight loss and improvement in comorbidity:differences at 5%, 10%, 15%, and over. Curr Obes Rep 2017; 6: 187- 94.

[25] Hammoud R , Drucker DJ . Beyond the pancreas:contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol 2023; 19: 201- 16.

[26] Heise T , DeVries JH , Urva S et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care 2023; 46: 998- 1004.

[27] Samms RJ , Coghlan MP , Sloop KW . How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab 2020; 31: 410- 21.

[28] Jastreboff AM , Aronne LJ , Ahmad NN et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022; 387: 205- 16.

[29] Garvey WT , Frias JP , Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2):a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023; 402: 613- 26.

[30] Zhao L , Cheng Z , Lu Y et al. Tirzepatide for weight reduction in Chinese adults with obesity:the SURMOUNT-CN randomized clinical trial. JAMA 2024; 332: 551- 60.

[31] Sun X , Liu Z , Du T . Secular trends in the prevalence of abdominal obesity among Chinese adults with normal weight, 1993-2015. Sci Rep, 2021; 11: 16404.

[32] Hou X , Lu J , Weng J et al. Impact of waist circumference and body mass index on risk of cardiometabolic disorder and cardiovascular disease in Chinese adults:a national diabetes and metabolic disorders survey. PLoS One 2013; 8: e57319.

[33] Sun X , Yan AF , Shi Z et al. Health consequences of obesity and projected future obesity health burden in China. Obesity (Silver Spring) 2022; 30: 1724- 51.

[34] Bailey-Davis L , Wood GC , Benotti P et al. Impact of sustained weight loss on cardiometabolic outcomes. Am J Cardiol 2022; 162: 66- 72.

[35] Kheniser K , Saxon DR , Kashyap SR . Long-term weight loss strategies for obesity. J Clin Endocrinol Metab 2021; 106: 1854- 66.

RIGHTS & PERMISSIONS

The Author(s). Published by Oxford University Press on behalf of Higher Education Press.